Misplaced Pages

Edward Tobinick: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 20:23, 5 March 2021 editPythagimedes (talk | contribs)Extended confirmed users1,234 edits not relevant or helpful for this specific articleTags: Mobile edit Mobile web edit Advanced mobile edit← Previous edit Latest revision as of 16:29, 9 April 2021 edit undoBon courage (talk | contribs)Extended confirmed users66,214 edits boldly redirect since any mention makes more sense in target articleTag: New redirect 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
#REDIRECT ]
{{Infobox person
|name = Edward Tobinick
|birth_place = ], US
|nationality = American
|known_for = Perispinal ]
|alma_mater = ] (B.S. Biology, 1973)<br />] (M.D., 1977)
|occupation = Physician
|website = http://www.nrimed.com
}}

'''Edward Tobinick''' M.D. is an American ], ], and ], who invented the use of the drug ] for chronic neurological dysfunction after ] and ],<ref>{{cite news |last=Singh |first=Anita| title= Andrew Marr: how having a stroke changed my marriage for the better |url=https://www.telegraph.co.uk/news/2017/02/07/andrew-marr-having-stroke-changed-marriage-better/ |accessdate=November 17, 2018 |newspaper=]|date=February 7, 2017 }}</ref><ref>{{cite news |publisher=Springer Select |date=October 31, 2012 |title=New hope for survivors of stroke and traumatic brain injury | url=https://www.springer.com/about+springer/media/springer+select?SGWID=0-11001-6-1394543-0 |accessdate=November 17, 2018 }}</ref> with multiple issued U.S. and foreign patents, including U.S. patent 8,900,583.

== Selected publications ==
{| class="wikitable" style="font-size:90%"
|- style="text-align:center;"
! style="background:#B0C4DE;" | Year
! style="background:#B0C4DE;" | Article
! style="background:#B0C4DE;" | Journal&thinsp;/&thinsp;Textbook
|-
| rowspan="1" | 2010 || || Expert Review of Neurotherapeutics 2010 Jun;10(6):985-1002.
|-
| rowspan="1" | 2011 || || CNS Drugs 2011, 25(2): p.&nbsp;145-55.
|-
| rowspan="1" | 2012 || || CNS Drugs 2012, 26(12): p.&nbsp;1051–70.
|-
| rowspan="1" | 2014 || || CNS Drugs 2014, 25(2): p.&nbsp;145-55.
|-
| rowspan="1" | 2014 || || Clin Drug Investig 2014, 34(5): p.&nbsp;361-6.
|-
| rowspan="1" | 2016 || || CNS Drugs 2016 Jun;30(6):469-80.
|-
| rowspan="1" | 2017 || || New Therapeutics for Traumatic Brain Injury, K.A. Heidenreich, Editor. 2017, Academic Press/Elsevier: New York.
|-
| rowspan="1" | 2018 || || Expert Review of Neurotherapeutics 2018, 18(6): p.&nbsp;453-455.
|}

==References==
{{Reflist}}

== Selected patents==
{| class="wikitable" style="font-size:90%"
|- style="text-align:center;"
! style="background:#B0C4DE;" | Year Issued
! style="background:#B0C4DE;" | Inventor
! style="background:#B0C4DE;" | Title
! style="background:#B0C4DE;" | Country
|-
| rowspan="1" | 2009 || Edward Tobinick || || US
|-
| rowspan="1" | 2014 || Edward Tobinick || || US
|}
{{Authority control}}

{{DEFAULTSORT:Tobinick, Edward}}
]
]
]

Latest revision as of 16:29, 9 April 2021

Redirect to: